Patients with pulmonary arterial hypertension (PAH) who do not have an adequate response to therapy with phosphodiesterase-5 inhibitors (PDE-5i) may have insufficient synthesis of cyclic guanosine monophosphate (cGMP). These patients may respond to a direct soluble guanylate cyclase (sGC) stimulator such as riociguat. RESPITE (NCT02007629) was an open-label, multicenter, uncontrolled, single-arm phase 3b study of riociguat in patients with PAH who demonstrated an insufficient response to treatment with PDE-5i. Insufficient response was defined as World Health Organization functional class (WHO FC) III despite PDE-5i therapy for at least 90 days; 6-min walk distance (6MWD) of 165-440 m, and right-heart catheterization showing mean pulmonary artery pressure >30 mmHg, cardiac index <3.0 L/min/m, and pulmonary vascular resistance >400 dyn s cm. PAH patients with an insufficient response to stable doses of sildenafil or tadalafil-either as monotherapy or in combination with an endothelin receptor antagonist-for at least 90 days were switched to riociguat for 24 weeks. Starting at 1.0 mg TID, the dose of riociguat was increased during the 8-week titration phase in 0.5-mg increments in 2-week intervals if the patient had no signs or symptoms of hypotension. In the ensuing 16-week maintenance phase, riociguat was continued at the optimal individual dose. All efficacy outcomes were exploratory and include change from baseline to 24 weeks in 6MWD, cardiac index, N-terminal pro-brain natriuretic peptide, WHO FC, and quality of life and the proportion of patients with clinical worsening. The following biomarkers were to be measured: cGMP, asymmetric dimethyl arginine, growth-differentiation factor-15, and ST2. Results from RESPITE will help to determine if PAH patients who do not respond to PDE-5i are likely to benefit from treatment with an sGC stimulator. The study may also identify biomarkers that are able to suggest which patients are more likely to respond to sGC stimulators.
Preliminary data suggest that pts with pulmonary arterial hypertension (PAH) at intermediate risk on phosphodiesterase-5 inhibitors (PDE5i)-based therapy may benefit from switching to riociguat (RIO), a soluble guanylate cyclase stimulator. Here we compare switching to RIO vs continued PDE5i in intermediate-risk PAH pts not at treatment goal, including prespecified subgroups in the open-label, Phase 4 REPLACE study (NCT02891850). METHODS: Intermediate-risk PAH pts (WHO functional class [FC] III, 6-minute walk distance [6MWD] 165-440 m) on stable doses of PDE5i þ/endothelin receptor antagonist (ERA) were randomized to continue PDE5i or receive RIO up to 2.5 mg tid for 24 weeks. ERAs were continued in both arms. The blinded, centrally adjudicated composite primary endpoint was defined as no clinical worsening (CW) (death from any cause, hospitalization for worsening PAH, or disease progression) plus clinical improvement
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.